J B Chemicals & Pharmaceuticals Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/y83nrsltpkds3vlwh08zghrr.pdf

Key Takeaways


Domestic Formulations: The Growth Anchor

Chopra: "We are raising our operating margin guidance for the third year in row. EBITDA margins will be in the range of 27% to 29%. Once again, I will repeat, we are revising our operating EBITDA guidance for the third year in row."

CDMO: The Inflection Trade

Chopra: "These are four or five big projects which we will be able to commercialize by the end of the year. And starting next financial year, our run rate that we assume with all these businesses is seeing the daylight which today is around INR110 crore every quarter should be around INR150 crore every quarter."

Ophthal: The Embedded Margin Call Option

Khanna: "When the perpetual license triggers the gross margin profile changes significantly from the current conventional margin profile of closer to 20%, it will be much closer to our domestic gross margin profile. One can do the math and that's the significant upside we see kicking in, in our overall profitability."

International Formulations: Selective Growth, Margin Repair


Margins & Capital Allocation


Regulatory & Risk

Chopra: "Our plants also continue to get audited by US FDA, by other regulatory authorities and our people at the plants also have done a fantastic job in terms of facing those audits and not only no 483, no observations. That is what we can boast in terms of what we have delivered as a company."

Guidance & Commitments

CommitmentSpecificsTimeline
Operating EBITDA margin27%-29% range (ex-ESOP)FY26 (guidance raised for third straight year)
CDMO quarterly run-rate~₹150 crore (from ~₹110 crore currently)Starting next financial year (FY27)
CDMO growth rate12%-14%Ongoing from FY27
Gross margin improvement30-50 bps expansionFY26
Azmarda monthly run-rate140,000+ unitsBy end of H1 FY26 (next quarter)
Azmarda franchise size₹100 croreOver next 2-3 years
Ophthal revenue at license triggerClose to ₹230 croreDecember 2026 (perpetual license trigger)
Branded generic export growth~12% (from ~10% currently)From FY27 onwards
BGX growth10% short-to-medium term; 12%+ medium-to-long termFrom FY27 onwards
Capex₹100 crore per year (65-70% maintenance, 25-30% growth)Next two years
Depreciation increase4%-5%FY26
Other income (treasury)₹65-70 croreFY26
Dividend payout ratio~35%Ongoing
Anchor client additions (CDMO)At least 1-2 per yearOngoing
Productivity improvement12%-14% increaseOver next 2-3 years
India vs market growth premium3-4 percentage points above IPMOngoing

Key Metrics

MetricQ4 FY25
Revenue₹949 crore, +10% YoY
Operating EBITDA₹240 crore, +15% YoY
Operating EBITDA margin25.3%, +90 bps YoY
Net profit₹146 crore, +15% YoY
Gross margin66.1%, +90 bps YoY
Domestic business revenue₹519 crore, +11% YoY
Domestic business IQVIA growth13% YoY vs industry 7%
International business revenue₹430 crore, +9% YoY
CDMO revenue₹129 crore, +18% YoY
International formulations revenue₹282 crore, +6% YoY
Ophthal business revenue₹56 crore, +22% YoY
Chronic portfolio IQVIA growth16% YoY
Acute portfolio IQVIA growth10% YoY
Field force productivity8 lakh PCPM vs 4.6 lakh in FY21
Net cash₹689 crore as of 31 March 2025 vs ₹107 crore prior year
ROC32% vs 27% in FY24
ROE19.2%
Operating cash flow to operating EBITDA83%
FY26 operating EBITDA margin guidance27% to 29%, revised upward for third consecutive year
FY26 gross margin improvement guidance30 to 50 bps improvement
FY26 other income guidance₹65 to ₹70 crore as treasury income
FY26-27 capex guidance~₹100 crore per year
Dividend per share₹15.50 total for FY25, including ₹7 final and ₹8.50 interim